DSMB recommends continuation of effiKIR trial with two arms
Innate Pharma collaborates with NCIC Clinical Trials Group on the phase I/II trial of IPH2201 in ovarian cancer
First Phase II trial with IPH2201 open in head and neck cancer
Enrollment closed to new patients in the Phase I trial investigating lirilumab in combination with ipilimumab
ASH 2014 : Lirilumab enhances Elotuzumab activity in preclinical models
IPH 4102 preclinical data published in “cancer research”
Initiation of a Phase I clinical trial of lirilumab in combination with elotuzumab
Third data and safety monitoring board meeting for EffiKIR trial recommends continuation as planned
Orphan drug designation in the European Union for IPH4102
Highlights from Innate Pharma's R&D update
